Law firm Kessler Topaz Meltzer & Check, LLP has launched an investigation into Madrigal Pharmaceuticals following allegations of suppressed safety data. The inquiry stems from an October 9, 2026, whistleblower complaint by the company's former Head of Clinical Development, who alleged the firm hid liver-injury data and manipulated efficacy results for its drug Rezdiffra. Madrigal shares previously declined over 8% following the November 3, 2026, disclosure of these claims.
A whistleblower complaint filed October 9, 2026 by the former Head of Clinical Development alleges Madrigal suppressed adverse liver-injury data and presented unreproducible efficacy results for Rezdiffra, its only approved drug. The stock already fell over 8% on the disclosure, and this new securities-law investigation keeps the controversy alive, inviting further selling and litigation overhang in the coming days and weeks.
- ▼ KTMC investigation of potential federal securities-law violations announced November 17, 2026
- ▼ Whistleblower complaint dated October 9, 2026 alleging suppressed liver-injury data and unreproducible efficacy data for Rezdiffra
- ▲ Investigation is preliminary; no lawsuit or court ruling has yet followed
- ▲ Allegations are from a single former executive and remain unproven